NASDAQ:NTRA - Natera Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $126.36
  • Forecasted Upside: 9.92 %
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 11 Buy Ratings
  • 0 Strong Buy Ratings
▲ +4.1 (3.70%)

This chart shows the closing price for NTRA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Natera Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for NTRA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NTRA

Analyst Price Target is $126.36
▲ +9.92% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Natera in the last 3 months. The average price target is $126.36, with a high forecast of $160.00 and a low forecast of $60.00. The average price target represents a 9.92% upside from the last price of $114.96.

This chart shows the closing price for NTRA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 12 investment analysts is to buy stock in Natera. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/23/2021BTIG ResearchBoost Price TargetBuy$150.00 ➝ $155.00Medium
6/21/2021Wells Fargo & CompanyBoost Price TargetOverweight$110.00 ➝ $125.00High
6/21/2021SVB LeerinkBoost Price TargetPositive ➝ Outperform$140.00 ➝ $160.00High
6/15/2021Raymond JamesInitiated CoverageMarket PerformMedium
5/25/2021Truist SecuritiesLower Price TargetBuy$143.00 ➝ $129.00High
5/25/2021Wells Fargo & CompanyInitiated CoverageOverweight$110.00High
5/10/2021Morgan StanleyLower Price TargetOverweight$140.00 ➝ $135.00High
5/7/2021BTIG ResearchBoost Price TargetBuy$145.00 ➝ $150.00Medium
3/1/2021Morgan StanleyBoost Price TargetOverweight$87.00 ➝ $140.00Low
2/26/2021Piper SandlerBoost Price TargetTop Pick ➝ Overweight$127.00 ➝ $150.00Medium
1/27/2021TruistInitiated CoverageBuy$143.00High
1/20/2021SVB LeerinkBoost Price TargetOutperform$95.00 ➝ $140.00Low
1/19/2021BTIG ResearchBoost Price TargetBuy$112.00 ➝ $135.00Medium
1/14/2021Canaccord GenuityBoost Price TargetBuy$112.00 ➝ $125.00High
1/4/2021Craig HallumBoost Price TargetBuy$92.00 ➝ $118.00N/A
12/16/2020Piper SandlerBoost Price TargetPositive ➝ Overweight$92.00 ➝ $127.00High
12/2/2020BTIG ResearchBoost Price TargetAverage ➝ Buy$95.00 ➝ $105.00Medium
11/13/2020SVB LeerinkBoost Price TargetOutperform$84.00 ➝ $95.00Low
11/6/2020JPMorgan Chase & Co.Boost Price TargetOverweight$75.00 ➝ $90.00High
11/6/2020Morgan StanleyBoost Price TargetAverage ➝ Overweight$80.00 ➝ $87.00High
11/6/2020Piper SandlerBoost Price TargetOverweight$76.00 ➝ $92.00High
11/6/2020SVB LeerinkBoost Price TargetOutperform$75.00 ➝ $84.00High
10/7/2020BTIG ResearchInitiated CoverageBuy$90.00Medium
9/28/2020Morgan StanleyInitiated CoverageOverweight$80.00Medium
9/24/2020Craig HallumBoost Price TargetBuy$66.00 ➝ $82.00High
9/17/2020SVB LeerinkInitiated CoverageOutperform$75.00Low
9/2/2020Canaccord GenuityBoost Price TargetBuy$65.00 ➝ $72.00Low
8/6/2020Robert W. BairdBoost Price TargetOutperform$42.00 ➝ $60.00High
8/6/2020Canaccord GenuityBoost Price TargetBuy$55.00 ➝ $65.00High
8/6/2020JPMorgan Chase & Co.Boost Price TargetOverweight$45.00 ➝ $60.00High
6/22/2020Piper SandlerReiterated RatingBuy$63.00Low
5/21/2020CfraLower Price TargetBuy ➝ Hold$39.00 ➝ $36.00Low
5/14/2020Piper SandlerBoost Price TargetOverweight$49.00 ➝ $56.00Medium
5/7/2020Canaccord GenuityBoost Price TargetBuy$46.00 ➝ $48.00High
5/7/2020Robert W. BairdBoost Price TargetOutperform$40.00 ➝ $42.00High
5/7/2020JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$32.00 ➝ $45.00High
4/15/2020Canaccord GenuityReiterated RatingBuy$46.00Medium
4/15/2020CowenBoost Price TargetOutperform$32.00 ➝ $40.00Medium
3/19/2020Canaccord GenuityReiterated RatingBuy$46.00High
2/27/2020Piper SandlerBoost Price TargetOverweight$45.00 ➝ $49.00High
2/27/2020Canaccord GenuityReiterated RatingBuy$46.00High
12/19/2019Craig HallumReiterated RatingBuy$49.00High
11/7/2019Craig HallumBoost Price TargetBuy$37.00 ➝ $49.00High
11/4/2019JPMorgan Chase & Co.Boost Price TargetNeutral$27.00 ➝ $32.00High
10/18/2019CowenBoost Price TargetOutperform ➝ Average$30.00 ➝ $42.00Low
10/16/2019Canaccord GenuityReiterated RatingBuy$44.00High
10/11/2019Piper Jaffray CompaniesSet Price TargetBuy$45.00Low
9/25/2019Canaccord GenuityReiterated RatingBuy$44.00High
9/24/2019Piper Jaffray CompaniesBoost Price TargetOverweight$32.00 ➝ $45.00Low
9/11/2019Canaccord GenuityReiterated RatingBuy$38.00High
8/23/2019Canaccord GenuityBoost Price TargetBuy$36.00 ➝ $38.00High
8/22/2019Piper Jaffray CompaniesReiterated RatingBuyLow
8/8/2019Craig HallumBoost Price TargetBuy$29.00 ➝ $37.00High
8/8/2019Piper Jaffray CompaniesBoost Price TargetOverweight$28.00 ➝ $32.00High
8/8/2019Canaccord GenuityBoost Price TargetBuy$32.00 ➝ $36.00High
6/25/2019Canaccord GenuityBoost Price TargetTop Pick ➝ Buy$30.00 ➝ $32.00High
6/10/2019Piper Jaffray CompaniesBoost Price TargetAverage ➝ Overweight$23.00 ➝ $28.00High
4/21/2019Canaccord GenuityReiterated RatingBuy$27.00Medium
3/11/2019Canaccord GenuityReiterated RatingBuy$25.00High
11/9/2018CowenReiterated RatingBuy$30.00High
10/5/2018JPMorgan Chase & Co.Initiated CoverageNeutral ➝ Neutral$26.00High
9/28/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$21.00 ➝ $41.00High
8/16/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$25.00 ➝ $29.00Medium
8/9/2018Craig HallumBoost Price TargetBuy$23.00 ➝ $30.00High
8/9/2018Piper Jaffray CompaniesBoost Price TargetOverweight$27.00High
7/5/2018Piper Jaffray CompaniesReiterated RatingOverweight$18.00 ➝ $21.00High
6/28/2018Robert W. BairdBoost Price TargetOutperform ➝ Outperform$17.00 ➝ $20.00Low
6/28/2018Craig HallumSet Price TargetBuy ➝ Positive$16.00 ➝ $23.00High
6/25/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$16.00 ➝ $20.00High
6/25/2018Canaccord GenuityBoost Price TargetBuy ➝ Buy$19.00 ➝ $20.00High
5/9/2018Morgan StanleyBoost Price TargetOverweight ➝ Overweight$15.00 ➝ $16.00Low
4/9/2018Craig HallumInitiated CoverageBuy$16.00High
12/21/2017CowenReiterated RatingBuy$12.00Low
11/14/2017Canaccord GenuityReiterated RatingBuy$15.00N/A
10/24/2017Robert W. BairdReiterated RatingBuyN/A
10/6/2017Morgan StanleyReiterated RatingOverweight$13.00 ➝ $16.00N/A
9/1/2017CowenReiterated RatingBuy$14.00Low
8/7/2017Morgan StanleyLower Price TargetOverweight ➝ Overweight$18.00 ➝ $13.00Medium
5/10/2017Canaccord GenuityBoost Price TargetBuy$14.00 ➝ $16.00Medium
3/14/2017CowenLower Price TargetOutperform$17.00 ➝ $14.00Low
1/30/2017Canaccord GenuityReiterated RatingBuyN/A
1/23/2017Canaccord GenuityReiterated RatingBuy$18.00N/A
1/17/2017Canaccord GenuityReiterated RatingBuy$18.00N/A
1/6/2017Canaccord GenuityInitiated CoverageBuy$18.00N/A
11/10/2016BenchmarkBoost Price TargetBuy$16.00 ➝ $20.00N/A
8/5/2016Morgan StanleySet Price TargetBuy$20.00N/A
(Data available from 6/23/2016 forward)
Natera logo
Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to analyze chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that allows laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is headquartered in San Carlos, California.
Read More

Today's Range

Now: $114.96
Low: $111.21
High: $116.98

50 Day Range

MA: $100.15
Low: $86.05
High: $115.92

52 Week Range

Now: $114.96
Low: $44.57
High: $127.19


1,576,088 shs

Average Volume

912,133 shs

Market Capitalization

$10.11 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Natera?

The following Wall Street research analysts have issued stock ratings on Natera in the last year: BTIG Research, Canaccord Genuity, Craig Hallum, JPMorgan Chase & Co., Morgan Stanley, Piper Sandler, Raymond James, Robert W. Baird, SVB Leerink LLC, Truist, Truist Securities, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for NTRA.

What is the current price target for Natera?

11 Wall Street analysts have set twelve-month price targets for Natera in the last year. Their average twelve-month price target is $126.36, suggesting a possible upside of 9.9%. SVB Leerink LLC has the highest price target set, predicting NTRA will reach $160.00 in the next twelve months. Robert W. Baird has the lowest price target set, forecasting a price of $60.00 for Natera in the next year.
View the latest price targets for NTRA.

What is the current consensus analyst rating for Natera?

Natera currently has 1 hold rating and 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe NTRA will outperform the market and that investors should add to their positions of Natera.
View the latest ratings for NTRA.

What other companies compete with Natera?

How do I contact Natera's investor relations team?

Natera's physical mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The medical research company's listed phone number is 650-249-9090 and its investor relations email address is [email protected] The official website for Natera is